83 related articles for article (PubMed ID: 28881608)
1. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.
Ren Y; Zheng J; Fan S; Wang L; Cheng M; Shi D; Zhang W; Tang R; Yu Y; Jiao L; Ni J; Yang H; Cai H; Yin F; Chen Y; Zhou F; Zhang W; Qing W; Su W
Oncotarget; 2017 Aug; 8(31):50832-50844. PubMed ID: 28881608
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models.
Wu X; Zhang J; Zhen R; Lv J; Zheng L; Su X; Zhu G; Gavine PR; Xu S; Lu S; Hou J; Liu Y; Xu C; Tan Y; Xie L; Yin X; He D; Ji Q; Hou Y; Ge D
J Transl Med; 2012 Aug; 10():180. PubMed ID: 22935382
[TBL] [Abstract][Full Text] [Related]
3. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.
Hanawa M; Suzuki S; Dobashi Y; Yamane T; Kono K; Enomoto N; Ooi A
Int J Cancer; 2006 Mar; 118(5):1173-80. PubMed ID: 16161046
[TBL] [Abstract][Full Text] [Related]
4. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
[TBL] [Abstract][Full Text] [Related]
5. Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression.
Miyai K; Yamamoto S; Asano T; Tamai S; Matsubara O; Tsuda H
Cancer Sci; 2010 Sep; 101(9):1970-6. PubMed ID: 20608935
[TBL] [Abstract][Full Text] [Related]
6. Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
Nishimura T; Nakamura K; Yamashita S; Ikeda S; Kigure K; Minegishi T
BMC Cancer; 2015 Dec; 15():957. PubMed ID: 26673416
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.
Mrhalova M; Plzak J; Betka J; Kodet R
Neoplasma; 2005; 52(4):338-43. PubMed ID: 16059652
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
[TBL] [Abstract][Full Text] [Related]
9. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.
Lee HJ; Xu X; Choe G; Chung DH; Seo JW; Lee JH; Lee CT; Jheon S; Sung SW; Chung JH
Lung Cancer; 2010 Jun; 68(3):375-82. PubMed ID: 19712993
[TBL] [Abstract][Full Text] [Related]
10. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
11. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study.
Suzuki S; Dobashi Y; Sakurai H; Nishikawa K; Hanawa M; Ooi A
Cancer; 2005 Mar; 103(6):1265-73. PubMed ID: 15712203
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor expression and KRAS and BRAF mutations: study of 39 sinonasal intestinal-type adenocarcinomas.
Projetti F; Durand K; Chaunavel A; Léobon S; Lacorre S; Caire F; Bessède JP; Moreau JJ; Coulibaly B; Labrousse F
Hum Pathol; 2013 Oct; 44(10):2116-25. PubMed ID: 23791006
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
14. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
15. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.
Willmore-Payne C; Holden JA; Layfield LJ
Hum Pathol; 2006 Jun; 37(6):755-63. PubMed ID: 16733218
[TBL] [Abstract][Full Text] [Related]
16. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Berns EM; Casado A; Lambrechts D; Jimeno A; ; ; ; ; ;
Target Oncol; 2015 Dec; 10(4):583-96. PubMed ID: 26004768
[TBL] [Abstract][Full Text] [Related]
18. EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.
Martin V; Zanellato E; Franzetti-Pellanda A; Molinari F; Movilia A; Paganotti A; Deantonio L; De Dosso S; Assi A; Crippa S; Boldorini R; Mazzucchelli L; Saletti P; Frattini M
Histol Histopathol; 2014 Apr; 29(4):513-21. PubMed ID: 24122611
[TBL] [Abstract][Full Text] [Related]
19. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
[TBL] [Abstract][Full Text] [Related]
20. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]